Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084689 | 0.84 | ALOX15 (0.58) | CYP17A1CYP19A1BCAT1HSP90AA1CKS1B | |
| SCHEMBL22822742 | 0.80 | HSP90AA1 (0.46) | HSP90AA1CKS1BSKP1SKP2NPC1 | |
| SCHEMBL6083476 | 0.79 | ALDH1A1 (0.49) | CYP17A1CYP19A1NPC1ALDH1A1LMNA | |
| SCHEMBL6085211 | 0.77 | FAAH (0.59) | MGAMHPGDSNPC1ALDH1A1LMNA | |
| SCHEMBL11575818 | 0.76 | FAAH (0.51) | CYP17A1CYP19A1HSP90AA1CKS1BSKP1 | |
| SCHEMBL9715583 | 0.76 | MGAM (0.69) | MGAMCHRNB2CHRNA7CHRNA4CFTR | |
| SCHEMBL5511161 | 0.75 | MGAM (0.49) | MGAMCHRNB2CHRNA7CHRNA4CFTR | |
| SCHEMBL29281919 | 0.74 | MGAM (0.67) | MGAMCHRNB2CHRNA7CHRNA4CFTR | |
| SCHEMBL8129733 | 0.74 | HSP90AA1 (0.48) | CYP17A1CYP19A1HSP90AA1CKS1BSKP1 | |
| SCHEMBL29505143 | 0.73 | ALOX15 (0.65) | MGAMCHRNB2CHRNA7CHRNA4CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1554649-A | Metabotropic glutamate receptor antagonists for treating central nervous system diseases | NPSҩ������˾ | 2004-12-15 | — | — | CN | claimed |
| CN-1285820-A | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPS PHARMA INC (US) | 2001-02-28 | — | — | CN | claimed |
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| CN-1554649-A | Metabotropic glutamate receptor antagonists for treating central nervous system diseases | NPSҩ������˾ | 2004-12-15 | — | — | CN | disclosed |
| CN-1158264-C | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPSҩ������˾ | 2004-07-21 | — | — | CN | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| CN-1285820-A | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPS PHARMA INC (US) | 2001-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | MGAM 3566/4885CHRNB2 101/4885CHRNA7 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.